On 16 February 2017, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2016.
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 13:00 CET. The event will be hosted by Sobi’s CEO and President, Geoffrey McDonough, and the presentation will be held in English.
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference.
To participate in the telephone conference, please call:
UK: +44 203 008 9809
SE: +46 8 566 426 93
US: +1 855 831 5948
Live audience URL:
(The recording will be made available via the audience URL within three hours after the live broadcast.)
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
For more information please contact
|Linda Holmström, Senior Communications Manager
||Jörgen Winroth, Vice President, Head of Investor Relations
|+46 70 873 40 95
||+1 347-224-0819, +1 212-579-0506, +46 8 697 2135